1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Vivesto AB

Vivesto AB

VIVE.ST
Vivesto ABSE flagStockholm Stock Exchange
8.49
SEK
-0.17
- -
45.67MMarket Cap
Vivesto AB
VIVE.ST
(Stockholm Stock Exchange)

Recent

price

8.49

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
44.55
0.13
0.86
- -
0.04
1.23
3.59
0.08
1.09
0.59
44.1
5.08
0.18
- -
- -
- -
- -
Revenue per Share
-24.71
-79.29
-63.65
-56.85
-69.02
-69.74
-79.75
-77.15
-40.71
-59.69
-2.3
-25.76
-62.93
-20.83
-5.6
-4.8
-4.88
Basic EPS, GAAP
-139.92
-187.85
-124.59
-104.91
-80.49
-76.39
-83.43
-67.87
-50.05
-38.8
-4.31
-34.92
-15.18
-11.23
-6.65
-7.56
-5.4
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-79.34
-143.3
-178.7
-199.72
-235.75
-282.11
-347.03
-373.11
-306.07
-324.78
-236.72
-263.33
-305.06
-297.14
-264.12
-268.88
-277.87
Book Value per Share
-10.3
69.71
-52.93
-29.89
-70.79
-17.4
-53.97
-73.53
-43.81
-17.83
82.2
21.22
23.62
9.33
3.26
-2.63
3.52
Tangible Book Value per Share
1
1
1
1
2
2
2
2
3
3
5
5
6
6
7
7
7
Basic Weighted Avg Shares
31
- -
1
- -
- -
2
6
- -
3
2
202
26
1
- -
- -
- -
- -
Sales/Revenue/Turnover
-48.67
-60,709.43
-7,354.77
- -
-170,568.33
-5,234.98
-2,082.11
-81,792.44
-3,278.04
-7,613.59
-15.07
-502.14
-35,243.55
- -
- -
- -
- -
Operating Margin (%)
4
5
5
5
5
5
5
5
5
31
20
29
252
57
3
2
1
Depreciation Expense
-17
-66
-66
-72
-105
-117
-142
-160
-118
-201
-11
-133
-357
-129
-40
-34
-33
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-55.48
-62,226.42
-7,370.37
- -
-175,186.67
-5,676.18
-2,220.92
-93,164.53
-3,723.79
-10,166.92
-5.22
-506.73
-35,134.19
- -
- -
- -
- -
Profit Margin (%)
-12
46
-64
-63
-131
-52
-117
-171
-143
-44
355
97
129
57
23
-19
23
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9
5
5
- -
- -
- -
- -
LT Debt
142
294
273
319
282
376
326
300
345
383
819
550
326
198
158
125
167
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
13
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
11
Market Capitalization
136
70
54

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6
5
35
Cash, Cash Equivalents & STI
1
2
31
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
16
24
11
Payables & Accruals
- -
- -
- -
ST Debt
- -
13
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.56%
-30.84%
-21.32%
Free Cash Flow
64.01%
144.32%
13.58%
Net Income, GAAP
116.46%
236.29%
-14.27%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.36
-1.68
-1.66
-1.73
-5.6
2025
-1.54
-1.54
-1.16
-1.47
-4.8
2026
-0.84
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
Daewoong pharmaceutical Co.,Ltd (069620.KS)
Malin Corporation plc (MLC.IR)
4Front Ventures Corp. (FFNTF)
Priority Aviation, Inc. (PJET)
Lifecore Biomedical, Inc. (LFCR)
Business
Vivesto AB (VIVE.ST), a Swedish pharmaceutical company headquartered in Solna, develops and commercializes oncology drugs utilizing proprietary XR-17 technology platform to create water-soluble micellar formulations that enhance drug efficacy and safety profiles. Founded in 1988 and formerly known as Oasmia Pharmaceutical AB until its rebranding in March 2022, the company focuses on hard-to-treat cancers in humans and veterinary applications; its core pipeline includes Apealea (paclitaxel micellar), a marketed treatment for platinum-resistant ovarian cancer commercialized through partnerships such as with Elevar Therapeutics; Cantrixil (TRX-E-002-1), a tubulin inhibitor in preclinical development for hematological cancers including blood malignancies; Docetaxel micellar, in clinical stages for advanced prostate cancer; and Paccal Vet (paclitaxel micellar), a veterinary oncology product under evaluation in pilot clinical trials for dogs with splenic hemangiosarcoma post-splenectomy and in dose-finding studies for cats with solid tumors; the company also maintains Doxophos Vet (doxorubicin formulation) for canine lymphoma in its animal health portfolio. Vivesto operates primarily in Europe with global commercialization ambitions through strategic alliances and targets patients with advanced cancers alongside veterinary markets. Recent developments include the March 2025 acquisition of full global rights to Cantrixil from Kazia Therapeutics for USD 1 million following positive preclinical data in hematological cancers, supporting accelerated manufacturing for clinical trials and new IP filings; in November 2025, the company announced a fully secured rights issue of approximately SEK 53.8 million to fund Paccal Vet and Cantrixil advancement toward partnerships anticipated in 2026-2027; positive interim progress in Paccal Vet trials and Q3 2025 financial reporting underscore ongoing pipeline momentum.